How much does serpatinib reimburse when included in medical insurance?

Selpercatinib (Selpercatinib) is an important drug for the treatment of cancers with RET gene fusions or mutations, especially in the treatment of non-small cell lung cancer and medullary thyroid cancer. However, the price factor often bothers patients. In this context, medical insurance policy has become the key to reducing financial pressure on patients.

If serpatinib can be included in medical insurance, patients will be able to enjoy significant reimbursement discounts when purchasing this drug. Take the current market price of serpotinib, which is about RMB 10,000, as an example. Once included in medical insurance, according to the common reimbursement ratio of 70% (note that the actual reimbursement ratio may vary depending on the hospital level, for example, a tertiary hospital may only reimburse 60% of this ratio), the actual out-of-pocket amount paid by the patient will be significantly reduced.

Coverage by medical insurance not only means lower costs directly paid by patients, but also represents a simplification and convenience of the drug purchase process. Drugs in the medical insurance catalog are usually supplied through formal channels. Patients can purchase them at hospitals or designated pharmacies, and settle them directly through the medical insurance system. This not only ensures the reliable source of medicines, but also greatly facilitates patients.

However, it is worth noting that in order for drugs to be included in the medical insurance catalog, they must go through a series of strict reviews and price negotiations. This is a process involving the interests of many parties and requires joint negotiation between pharmaceutical companies and the medical insurance department to ensure the reasonableness of drug prices and the sustainable use of medical insurance funds.

In summary, if serpatinib can be successfully included in medical insurance, patients will be able to enjoy significant reimbursement benefits and receive treatment more effectively. We look forward to the continuous improvement of the medical insurance system, so that innovative drugs such as Serpatinib can benefit the majority of patients earlier and bring substantial improvements to their health and quality of life.